anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AMA1-C1 with Montanide ISA 720, is a blood stage malaria vaccine candidate. The objectives of this phase 1 trial are to study the safety, reactogenicity, and immunogenicity of this vaccine and to assess the level, kinetics, and the in vitro biological activity of the antibody response it induces. The study is an open label, dose escalation, phase 1 clinical trial in healthy adult volunteers. Volunteers will be screened and 28 participants will be enrolled into 3 dose cohorts. Cohort 1 will receive 5 micrograms of AMA1-C1/ISA 720 at each injection, Cohort 2 will receive 20 micrograms, and Cohort 3 will receive 80 micrograms. Cohorts 1 and 2 will receive 2 injections, 3 months apart. Cohort 3 will receive only 1 vaccination. Safety outcome measures are local and systemic (including laboratory) adverse events. Immune responses to vaccination will be measured by enzyme-linked immunosorbent assay (ELISA) and parasite growth inhibition assay (GIA), and will be compared among dose groups.
The report generation unit restricts the generation of duplicate examination reports for each examination. In an ultrasonic diagnostic apparatus, when a report generation start instruction is given by a user, a report generation unit is activated. For example, the user inputs the observation result or the like into the inspection report. When a report generation end instruction from a user is issued, a report generation unit generates an inspection report indicating the contents of the instruction time. At the end of the inspection, an inspection report is automatically sent to the workstation. When the examination report is not generated at the end of the examination, the report generation unit automatically generates the examination report. The inspection report is also automatically sent to the workstation at this time.
Viral chimer (I) comprising a capsid and/or a lipidic envelop integrating the constituents of viral pathogen, a defective genome phylogenically close to the viral pathogen obtained from genetic construction, a genome having the capacity to serve a helper virus in vivoor ex vivo, and a genome comprising nucleotidic sequences encoding for polypeptides implied in the antigenicity of virus, is new. Viral chimer (I) comprises: (a) a capsid and/or a lipidic envelop integrating the constituents of a viral pathogen responsible for the specific recognition of membrane receptors of cells infected by the virus, and also all the other viral constituents of viral pathogen necessary for the penetration of viral pathogen genome in the infected cells; (b) a defective genome phylogenically close to one of the viral pathogen, obtained from genetic construction, which makes the single chimer incapable, after penetration in the target cells, to generate the intracellular synthesis of polypeptides obtained from its genome; (c) a genome obtained from genetic construction so that the viral pathogen has the capacity to serve helper virus in vivoor ex vivofor the chimer and the presence of pathogen virus catalyze the intracellular synthesis obtained from the genome of the chimer, and the same cells are co-infected by the pathogen virus and the chimer; and (d) a genome from a genetic construction comprising one or more nucleotidic sequences encoding for one or more polypeptides implied in the antigenicity of viral pathogen, in which the polypeptides contain one or more epitopes identical to those against which one or more known vaccines direct the immunity. Independent claims are also included for: (1) a pharmaceutical composition (II) useful in the prophylaxis or treatment of viral diseases or influenza A virus comprising (I) and optionally an additive, a diluent, an excipient and/or a vehicle; (2) detecting and/or quantifying a viral infection comprising detecting a previously detected human or animal biological sample in humans/animals that are previously vaccinated with the vaccine and previously received the administration of a composition in which the antibody directed against the coded antigens by the genome of the chimers and optionally the antibodies of are quantified with respect to a concentration of reference; and (3) a chimeric influenza A virus comprising proteins of envelop M 2, HA and NA having little or no circulation within a human population and not generating a weak immune reaction, in vivo when administering within the population; proteins PA and/or NP and/or PB 1and/or PB 2, of which the sequences of amino acids were modified in such a manner that the RNA viral polymerase constitutive of cRNP of the chimeric virus with lost properties of catalysing mRNA or synthesis of these mRNA is negligible but having conserved its properties of replication of genome and a genome comprising combinations of (I). ACTIVITY : Virucide. No biological data is given. MECHANISM OF ACTION : Vaccine.
Syncope can have devastating consequences, resulting in injuries, accidents or even death. In our ageing society, the subsequent healthcare usage, such as emergency room presentations, surgeries and hospital admissions, forms a significant and growing socioeconomic burden. Causes of syncope in the older adult include orthostatic hypotension, carotid sinus syndrome, vasovagal syncope, structural cardiac abnormalities, cardiac arrhythmias and conduction abnormalities. As stated in the recently published World Falls Guidelines, syncope in older adults often presents as falls, which is either due to amnesia for loss of consciousness, or pre-syncope leading to a fall, especially in those prone to falls with several other risk-factors for falls present. This difference in presentation can hinder the recognition of syncope. In patients with unexplained falls, or in whom the history comprises red flags for potential syncope, special attention to (pre)syncope is therefore warranted. When syncope is mistaken for other causes of a transient loss of consciousness, such as epileptic seizures, or when syncope presents as falls, patients are often referred to multiple specialists, which may in turn lead to excessive and unnecessary diagnostic testing and costs. Specialist services that are able to provide a comprehensive assessment can improve diagnostic yield and minimise diagnostic testing, thus improving patient satisfaction. Comprehensive assessment also leads to reduced length of hospital stay. Increasingly, geriatricians are involved in the assessment of syncope in the older patient, especially given the overlap with falls. Therefore, awareness of causes of syncope, as well as state-of-the-art assessment and treatment, is of great importance.
Little is known about the key determinants of the physiological adaptations to environmental challenges and how these determinants interact. We evaluated how the response/recovery profiles to a short-term nutritional challenge during early lactation are affected by early-life nutritional strategies in dairy goats divergently selected for functional longevity. We used 72 females, split into two cohorts, daughters of Alpine bucks divergently selected for functional longevity. The females from the two lines were fed with two divergent diets, normal vs low-energy, from weaning until the middle of first gestation, and then fed with the same standard diet. Individual BW, body condition score, morphology, and plasma samples were collected from birth to first kidding. The adaptative physiological strategy to a nutritional challenge was assessed via a 2-day feed restriction challenge, during early lactation, which consisted of a five-day control period on a standard lactation diet followed by a 2-day challenge with straw-only feeding and then a 10-day recovery period on a standard lactation diet. During the challenge, DM intake, BW, milk yield (MY), and plasma and milk metabolite composition were recorded daily. Linear mixed-effects models were used to analyze all traits, considering the individual nested in the cohort as a random effect and the 2 × 2 treatments (i.e., line and rearing diet) and litter size as fixed effects. Linear mixed-effects models using a piecewise arrangement were used to analyze the response/recovery profiles to nutritional challenge. Random parameters estimated for each individual, using the mixed-effects models without the fixed effects of rearing diet and genetic line, were used in a stepwise model selection based on R2 to identify key determinants of an individual's physiological adaptations to environmental challenges. Differences in stature and body reserves created by the two rearing diets diminished during late gestation and the 5-day control period. Genetic line did not affect body reserves during the rearing phase. Rearing diet and genetic line slightly affected the recovery profiles of evaluated traits and had no effects on prechallenge and response to challenge profiles. The prekidding energy status measures and MY before challenge were selected as strong predictors of variability in response-recovery profiles of milk metabolites that have strong links with body energy dynamics (i.e., isoCitrate, ß-hydroxybutyrate, choline, cholesterol, and triacylglycerols; R2 = 35%). Our results suggested that prekidding energy status and MY are key determinants of adult resilience and that rearing diet and genetic line may affect adult resilience insofar as they affect the animals' energy status.
Hedgehog pathway inhibitors (HHIs) have broadened the treatment options available for patients with advanced basal cell carcinoma (BCC) for whom traditional therapeutic approaches are not feasible or effective. Sonidegib and vismodegib are oral HHIs that were approved for treatment of patients with advanced BCC after demonstrating promising efficacy in the pivotal Phase II BOLT (NCT01327053) and ERIVANCE (NCT00833417) trials, respectively. However, the incidence and types of treatment-emergent adverse events (AEs) observed with these agents may limit continuous use of HHIs and ultimately impact clinical outcomes. In this review, we summarize the safety and tolerability profiles of sonidegib and vismodegib and discuss potential management strategies for HHI class-effect AEs, including muscle spasms, creatine phosphokinase increase, alopecia, and dysgeusia. These AEs primarily occur early in treatment and can lead to treatment discontinuation. Differences in the pharmacokinetic profiles of sonidegib and vismodegib may contribute to the variability noted in times to onset and resolution of these and other AEs. Evidence suggests that protocol modifications, such as treatment interruptions and dose reductions, are effective ways to manage AEs while maintaining disease control. Nonpharmacologic and pharmacologic interventions may also be considered as part of an AE management strategy. Overall, healthcare providers and patients with advanced BCC should be aware of the HHI class-effect AEs and plan effective management strategies to avoid treatment discontinuation and optimize therapeutic response.
The invention discloses a medicament composition for curing over-dried vagina, dyspareunia, dysmenorrheal and leucorrhea diseases. The medicine composition is mainly composed of raw medicines according to the part by weight, such as camellia oil 400 parts, cinnamomum cassia, evodia rutaecarpa and rhizoma zedoariae which are respectively 200 parts, cnidium fruit, safflower and curculigo rhizome which are separately 150 parts and pricklyash peel 50 parts. The medicine composition of the invention is capable of warming yang, dispersing cold, promoting blood circulation, freeing channel, smoothing and relieving itch and is adaptable for women with over-dried vagina, cold womb, hyposexuality and dyspareunia. Furthermore, the invention can be used to cure female diseases caused by asthenia-cold of kidney and liver, such as dull pain of the lower abdomen, irregular menstruation, dysmenorrheal and leucorrhea diseases, and treat impotence of men. The invention is simple in dispensation and easy in production. The medicine composition of the invention employs pure Chinese herbal medicine to produce and has the advantages of obvious curing effect, little toxic and side effects and convenient utilization, thereby having wide application value.
The control group will be provided the usual antenatal dietary advice. This includes advice on healthy and physical activity in women with normal weight and obesity and overweight. Folic acid and vit D supplementation are provided as per national recommendations. Participants will provide outcome data at point of delivery and food frequency questionnaire at baseline and 36 weeks or delivery depending on which is sooner.
Studies suggest that dietary calcium intake is inversely associated with cardiovascular disease, but supplementary calcium appears to be associated with raised risk of cardiovascular events. Fatty meals lead to oxidative and inflammation which seems to interfere in postprandial dismetabolism, a predictor of cardiovascular events. To investigate calcium acute influence over the postprandial effects of a fatty meal a crossover, controlled, and randomized clinical trial will be conducted with obese adult women who will be randomized into one of the three interventions, characterized by a fatty meal with different contents of calcium: low calcium (40 mg), high dietary calcium (540 mg from non-fat milk), and high supplementary calcium (540 mg from calcium carbonate). Each participant will receive all three meals and one of them every week. Before meals' intake blood sample will be collected and endothelial function assess will be performed. Participants will eat the specific meal and endothelial function will be assessed again after 120 minutes. Blood sample collections will be repeated every 60 minutes after meal's intake to perform latter biochemical analyzes to determine: 8-isoprostane levels, to assess oxidative stress status; triglycerides; glucose; insulin; and serum calcium. Blood pressure will be continuously assessed during 25 minutes before meals' intake and during 2 hours after it.
Chronic kidney disease (CKD) is a global health burden, with ineffective therapies leading to increasing morbidity and mortality. Renal interstitial fibrosis is a common pathway in advanced CKD, resulting in kidney function and structure deterioration. In this study, we investigate the role of FTO-mediated N6-methyladenosine (m6A) and its downstream targets in the pathogenesis of renal fibrosis. M6A modification, a prevalent mRNA internal modification, has been implicated in various organ fibrosis processes. We use a mouse model of unilateral ureteral obstruction (UUO) as an in vivo model and treated tubular epithelial cells (TECs) with transforming growth factor (TGF)-β1 as in vitro models. Our findings revealed increased FTO expression in UUO mouse model and TGF-β1-treated TECs. By modulating FTO expression through FTO heterozygous mutation mice (FTO+/- ) in vivo and small interfering RNA (siRNA) in vitro, we observed attenuation of UUO and TGF-β1-induced epithelial-mesenchymal transition (EMT), as evidenced by decreased fibronectin and N-cadherin accumulation and increased E-cadherin levels. Silencing FTO significantly improved UUO and TGF-β1-induced inflammation, apoptosis, and inhibition of autophagy. Further transcriptomic assays identified RUNX1 as a downstream candidate target of FTO. Inhibiting FTO was shown to counteract UUO/TGF-β1-induced RUNX1 elevation in vivo and in vitro. We demonstrated that FTO signaling contributes to the elevation of RUNX1 by demethylating RUNX1 mRNA and improving its stability. Finally, we revealed that the PI3K/AKT pathway may be activated downstream of the FTO/RUNX1 axis in the pathogenesis of renal fibrosis. In conclusion, identifying small-molecule compounds that target this axis could offer promising therapeutic strategies for treating renal fibrosis.
The system disclosed allows a user to specify an illness, disease, or health condition, mental or physical or otherwise, and interconnect with other users having similar diagnoses, symptoms, conditions, complications, treatments, or otherwise. The patient user may be connected to a caregiver who links into the system to connect with other caregivers as well. The digital platform is a health web designed to interconnect patients, friends, families, doctors or others who seek personalized medical information pertaining to the experiences of others, creating models for treatment of persons within and external to medical settings. Such models may be real or simulated by artificial intelligence (AI). In creating decision trees within the digital platform, real and synthetic data can be incorporated. The system creates an AI-driven large learning model (LLM) to impact persons health and provider care, globally.
In a prospective observational study the investigators aim to study the ability of modern antirheumatic treatments to suppress levels of survivin in sera. Rheumatoid arthritis patients scheduled to start new pharmacological treatment will be followed for a period of 6 months. No intervention or influence on choice of treatment will be performed, the decision of new/other medication is entirely made by the patient and their rheumatologist. The study entails addition of survivin analyse (1 vial of sera) before and after start of new treatment. Data concerning survivin levels, disease activity and other clinical parameters before and after start of new treatment will also be analysed. The patients will leave sera for survivin analyse at baseline and 3 and 6 months after start of new treatment.
A cis-lycopene preparation boosting immunity and a preparing method thereof are disclosed. The cis-lycopene preparation comprises 2.5-11 parts by weight of a raw material rich in cis-lycopene and 0.5-5.23 parts by weight of conventional pharmaceutic adjuvants. The raw material rich in cis-lycopene is prepared by (1) fully mixing lycopene oleoresin with beta-cyclodextrin to form a lycopene-beta-cyclodextrin mixture, and (2) treating the lycopene-beta-cyclodextrin mixture through heating or microwaves under vacuum to convert trans-lycopene into cis-lycopene until the water content is lower than 10.0% so as to obtain the raw material rich in cis-lycopene. The cis-lycopene preparation boosting immunity is provided. The content of the cis-lycopene in the preparation reaches 2% and is stable. The preparation has an effect of boosting immunity.
Objective: Periodontally accelerated osteogenic orthodontics(PAOO) combines periodontal therapy with orthodontic therapy, which will minimize treatment time. The current study will be carried to evaluate the effectiveness of bovine derived xenograft versus bioactive glass with a modified, less invasive corticotomy technique in the treatment of adult patients with moderate crowding.

Subjects and Methods: Thirty orthodontic patients will be selected. Patients were randomly classified into three groups. Group I will be treated with a modified technique of corticotomy on the labial side only, whereas group II will be treated with the same technique combined with PAOO using bovine derived xenograft, and group III will be treated with the same technique combined with PAOO using with bioactive glass. The total duration of active orthodontic treatment will be estimated from the time of starting the active orthodontic treatment, immediately following the corticotomy procedure, to the time of debonding. Probing depth will be evaluated clinically whereas bone density and root length will be evaluated radiographically. The measurements will be recorded at day of surgery (baseline) (T1), post-treatment at time of debonding (T2), and 9 months post-treatment (T3).
OBJECTIVE: A chest tube is usually placed in patients undergoing general thoracic surgery. Although the barbed suture method has been introduced for chest tube wound closure, its superiority to the conventional suture methods for drain management remains unclear. The study aimed to determine whether the barbed suture method could reduce drain-related adverse events compared to the conventional method.
METHODS: We retrospectively reviewed the medical records of patients who underwent general thoracic surgery between January 2021 and December 2022, 1 year before and after the introduction of the barbed suture method at our institution. Patients who underwent the barbed suture or conventional method were included. Univariate and multivariate analyses of drain-related adverse events were performed.
RESULTS: Of the 250 participants, 110 and 140 underwent the barbed suture method and conventional suture method, respectively. The univariate analysis showed that a higher body mass index, preoperative malignant diagnosis, lobectomy, longer operative time, larger tube size, longer chest drainage duration, surgical complications, and conventional method were risk factors for drain-related adverse events. The multivariate analysis showed that the barbed suture method was a protective factor against drain-related adverse events (odds ratio 0.267; 95% confidence interval 0.103-0.691; P = 0.007).
CONCLUSIONS: The barbed suture method could reduce drain-related adverse events compared to the conventional method. Therefore, it might be a potential standard method for chest tube wound closure in patients undergoing general thoracic surgery.
FIELD: pharmaceutical technology, pharmacy. SUBSTANCE: method for preparing drug-releasing material is carried out by swelling polyurethane film in the drug solution. Before drug addition a film made of polyurethane with space chemically cross-linked structure is kept in polar solvent for 1-30 h, dried under vacuum to constant weight and subjected for swelling in the drug solution that is inert with regard to solvent up to preparing equilibrium swelling degree followed by drying and treatment of surface under vacuum by high-energetic flow of ions. Treatment of surface under vacuum is carried out at voltage in impulse 20 keV, current density in impulse 15 mA/cm 2 , impulse time 5 mcs, with impulse frequency from 0.3 to 50 Hz and treatment dose from 10 13  to 10 16  ions/cm 2 . Invention provides preparing material with uniform drug release and prolonged effect. EFFECT: improved preparing method. 2 cl, 3 dwg, 3 ex
The invention relates to a guiding type exercise system, which comprises a servo platform, a plurality of exercise modules and a guiding module. The servo platform provides a plurality of exercise teaching cases and a guiding program. The exercise modules respectively comprise a first processing unit and an electromechanical component. The first processing unit executes the exercise instruction of at least one of the plurality of exercise teaching plans to drive the electromechanical component to be operated by the exerciser. The guiding module comprises a second processor and an indicating unit. The second processing unit executes the guide program and is capable of guiding the exerciser to move from the present exercise module to another exercise module through the instructing unit. The invention also provides a programmable guided exercise teaching plan method and a programmable guided exercise teaching plan system.